Table 2: Epidemiological characteristics, clinical manifestation, HScore, underlying disorders and mortality of each etiological subgroup of Hemophagocytic Syndrome during the admission.
|
Total |
AI |
HM |
Inf. |
MST |
HPS without defined etiology |
|
||||||
|
n |
30 |
10 |
12 |
2 |
1 |
5 |
p < 0.05 |
|||||
|
Age (x ± s) |
55.5 |
± 18.3 |
40 |
26.5-56.3 |
68 |
57.5-73.8 |
45.5 |
30-61 |
78 |
71 |
53.5-73.5 |
0.006 |
|
Gender, man |
14 |
46.70% |
3 |
30% |
9 |
75% |
1 |
50% |
1 |
0 |
0% |
|
|
Gender, women |
16 |
53.30% |
7 |
70% |
3 |
25% |
1 |
50% |
0 |
5 |
100% |
0.013 |
|
Splenomegaly |
16 |
53.30% |
5 |
50% |
8 |
66.70% |
2 |
100% |
0 |
1 |
20% |
0.216 |
|
Hepatomegaly |
10 |
33.30% |
4 |
40% |
4 |
33.30% |
2 |
100% |
0 |
0 |
0% |
0.138 |
|
Global hospital stay∞ |
35.5 |
20-60.8 |
30.5 |
9.5-53.3 |
61.5 |
29.3-93.3 |
23 |
16-30 |
28 |
23 |
16.5-59 |
0.191 |
|
Hospital stay previous to the diagnosis and treatment initiation∞ |
16.5 |
8.5-29.8 |
10 |
5-16.5 |
26 |
Oct-39 |
14 |
17-Nov |
13 |
36 |
11.5-50 |
0.191 |
|
ICU admission |
7 |
23.30% |
2 |
20% |
4 |
33.30% |
0 |
0% |
0 |
1 |
20% |
0.935 |
|
HScore |
270.5 |
248.2-302.5 |
272 |
249-304* |
277 |
261-311** |
294 |
268-319α |
229 |
246 |
240-251β |
0.164 |
|
Mortality |
13 |
43.30% |
1 |
10% |
8 |
66.70% |
1 |
50% |
0 |
3 |
60% |
0.029 |
∞[Median; RIQ].
*One patient did not have a fibrinogen measurement and had 264 points on the HScore.
**Two patients had no fibrinogen measurement and had 210 and 272 points on the HScore. One patient did not have fibrinogen and ferritin measurements, and had 224 points on the HScore.
αOne patient did not have a fibrinogen measurement and had 268 points on the HScore.
βOne patient did not have fibrinogen measurement and had 127 points on the HScore, but presented hemophagocytic cells in the bone marrow biopsy.